About us & our product
ImVitro’s SaaS platform EMBRYOLY is an AI-powered software. EMBRYOLY’s core feature provides a ranking based on the embryo’s morphokinetics as well as a subsequent transfer priority recommendation personalized to the patient for increased accuracy. See our product page for more information!
Many aneuploid embryos will not lead to a clinical pregnancy [Capalbo et al, 2022] – preimplantation genetic testing (PGT-A) is sometimes used in addition to morphological or morphokinetic evaluation to identify them, especially for patients above 35 y.o. who are at higher risks of having aneuploid embryos because of a decreasing oocyte quality.
EMBRYOLY’s score has been shown to be predictive of pregnancy potential, and thus to help deprioritize embryos for transfer. Is it also indicative of the embryo’s aneuploïdy potential? This would further confirm that EMBRYOLY’s score is a valuable data point to aid embryologists in deprioritizing embryos for transfer.
Questions to answer
- Can EMBRYOLY help deprioritize potential aneuploid embryos across all ages?
- Can EMBRYOLY rank embryos based on their likelihood of aneuploidy across all ages?
- How often does EMBRYOLY deprioritize potential aneuploid embryos for women >35 y.o., in a center where only embryos sent for PGT-A are considered vs. a center where PGT-A cannot be used?
The study at a glance
EMBRYOLY’s algorithms were applied on data coming from a Spanish clinic with N = 434 egg retrievals corresponding to N = 1324 embryos. Out of these, 896 embryos went through PGT-A, including N = 439 aneuploid (4.9%), N = 321 euploid (35.8%) and N = 86 mosaic embryos (9.6%). PGT-A results were categorized either as: aneuploid, mosaic, euploid or without diagnostic if the test did not work. The number of embryos that had been sent for PGT-A per egg retrieval was N = 3.05±2.08, corresponding on average to 74% of the cohort.
This data was acquired through a GERI® (Genea BiomedX) time-lapse system and not used in EMBRYOLY’s